Efekat fizikalne terapije u lečenju obolelih od cervikalne distonije sa ili bez istovremene primene botulinskog toksina

  • Ivona Stanković Univerzitet u Nišu, Medicinski fakultet, Katedra za fizikalnu medicinu i rehabilitaciju
  • Hristina Čolović Clinical Center Niš, Clinic for Physical Medicine and Rehabilitation, Niš, Serbia
  • Vesna Živković Clinical Center Niš, Clinic for Physical Medicine and Rehabilitation, Niš, Serbia
  • Jelena Stamenović University of Niš, Faculty of Medicine, Niš, Serbia
  • Anita Stanković Clinical Center Niš, Clinic for Physical Medicine and Rehabilitation, Niš, Serbia
  • Dragan Zlatanović Clinical Center Niš, Clinic for Physical Medicine and Rehabilitation, Niš, Serbia
  • Danijela Živković University of Niš, Faculty for Sports and Physical Education, Niš, Serbia
  • Tamara Stanković University of Niš, Faculty of Medicine, Niš, Serbia
DOI: https://doi.org/10.2298/VSP161115016S
Ključne reči: cervikalna distonija, primarna;, fizikalna terapija, metodi;, botulin, toksini;, klasifikacioni indeksi.

Sažetak


Uvod/Cilj. Primena botulinskog toksina predstavlja os­novnu, preporučenu metodu lečenja u kontroli cervikalne distonije (CD). Fizikalna terapija ima ograničene domete s obzirom na prirodu bolesti koja je posledica poremećaja u strukturama i vezama bazalnih ganglija. Cilj ovog rada bio je analiza efekta fizikalne terapije primenjene u smislu jedinog terapijskog modaliteta ili uz paralelnu primenu botulinskog toksina kod bolesnika sa CD. Metode. Randomno, kontrolisano kliničko istra­živanje po tipu pilot studije obuhvatilo je 14 bolesnika kod kojih je postavljena dijagnoza idiopatske CD. Kod svih bolesnika inicijalno je procenjena težina bolesti korišćenjem Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) i Torticollis Rating Scale (Tsui skala). U kontrolnoj grupi, sastavljenoj od 5 ispitanika, lečenje je podrazumevalo fizikalnu terapiju, a u eksperimentalnoj, sastavljenoj od 9 bolesnika, prvo je dat bo­tu­linski toksin, a posle pet dana je primenjena fizikalna terapija. Fizikalna terapija je primenjivana 5 dana ne­deljno tokom 10 dana na Klinici. Bolesnicima obe grupe je receno da nastave sa fizikalnom terapijom u kućnim uslovima. Efekti terapije analizirani su nakon 1, 3 i 6 meseci korišćenjem TWSTRS i Tsui skale. Rezultati. Na početku istraživanja, razlike u TWSTRS i Tsui skali između grupa nisu bile značajne.  U kontrolnoj grupi, nakon 1 meseca, postignuto je značajno poboljšanje u sva 3 dela TWSTRS. Nakon 3 i 6 meseci, efekat fizi­kal­ne terapije smanjen je do početnog nivoa. U eksperi­mentalnog grupi, postignuto je značajno poboljšanje svih praćenih parametara TWSTRS nakon 1, 3 i 6 me­seci. U kontrolnoj grupi, značajno smanjenje parametara u Tsui skali primećeno je samo nakon 1 meseca, dok se u eksperimentalnoj grupi održavalo i nakon 3 i 6 meseci. Zaključak.

Reference

REFERENCES

Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, et al. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. Neurology 2006; 67(12): 2233–5.

de Carvalho AP, Ozelius LJ. Classification and genetics of dys-tonia. Lancet Neurol 2002; 1(5): 316–25.

Gross AR, Hoving JL, Haines TA, Goldsmith CH, Kay T, Aker P, et al. Cervical overview group. Manipulation and mobilisation for mechanical neck disorders. Cochrane Da-tabase Syst Rev 2004; (1): CD004249.

Fabbri M, Superbo M, Defazio G, Scaglione CL, Antelmi E, Basini G, et al. Quality of life in patients with craniocervi¬cal dysto-nia: Italian validation of the "Cervical Dystonia Impact Pro-file (CDIP-58)" and the "Craniocervical Dysto¬nia Question-naire (CDQ-24)". Neurol Sci 2014; 35(7): 1053–8.

Jinnah HA, Factor SA. Diagnosis and Treatment of Dysto¬nia. Neurol Clin 2015; 33(1): 77–100.

Krauss JK, Toups EG, Jankovic J, Grossman RG. Sympto¬matic and functional outcome of surgical treatment of cer¬vical dys-tonia. J Neurol Neurosurg Psychiatr 1997; 63(5): 642–8.

Marsh WA, Monroe DM, Brin MF, Gallagher CJ. Systematic Review and Meta Analysis of the Duration of Clinical Ef¬fect of Onabotulinumtoxin A in Cervical Dystonia. BMC Neurol 2014; 14: 91.

Benecke R, Dressler D. Botulinum toxin treatment of axial and cervical dystonia. Disabil Rehabil 2007; 29(23): 1769–77.

Comella CL. The treatment of cervical dystonia with botuli-num toxins. J Neural Transm 2008; 115(4): 579–83.

Pappert EJ, Germanson T. Myobloc/Neurobloc European Cer-vical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial. Mov Dis¬ord 2008; 23(4): 510–7.

Albanese A, Bhatia K, Bressman SB, Delong MR, Fahn S, Fung VS, et al. Phenomenology and classification of dysto¬nia: a consensus update. Mov Disord 2013; 28(7): 863–73.

Crowner BE. Cervical dystonia. Disease profile and clinical management. Phys Ther 2007; 87(11): 1511–26.

Zetterberg L, Halvorsen K, Färnstrand C, Aquilonius SM, Lind-mark B. Physiotherapy in cervical dystonia: Six ex¬perimental single-case studies. Physiother Theory Pract 2008; 24(4): 275–90.

Cano SJ, Hobart JC, Fitzpatrick R, Bhatia K, Thompson AJ, Warn-er TT. Patient Based Outcomes of Cervical Dystonia: A Re-view of Rating Scales. Mov Disord 2004; 19(9): 1054–9.

Charles DP, Adler CH, Stacy M, Comella C, Jankovic J, Manack AA, et al. Cervical dystonia and pain: Characteris¬tics and treatment patterns from CD PROBE (Cervical Dystonia Pa-tient Registry for Observation of OnabotulinumtoxinA Effi-cacy). J Neurol 2014; 261(7): 1309–19.

Jen M, Kurth H, Iheanacho I, Dinet J, Gabriel S, Wasiak R, et al. Assessing the burden of illness from cervical dystonia using the Toronto Western Spasmodic Torticollis Rating Scale scores and health utility: A meta-analysis of baseline patient-level clinical trial data. J Med Econ 2014; 17(11): 803–9.

Hsiung GY, Das SK, Ranawaya R, Lafontaine AL, Suchower¬sky O. Long-term efficacy of botulinum toxin A in treat¬ment of var-ious movement disorders over a 10-year pe¬riod. Mov Disord 2002; 17(6): 1288–93.

Mejia NI, Vuong KD, Jankovic J. Long-term botulinum toxin ef-ficacy, safety, and immunogenicity. Mov Disord 2005; 20(5): 592–7.

Herrmann J, Geth K, Mall V, Bigalke H, Schulte Mönting J, Linder M, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 2004; 55(5): 732–5.

Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology 2003; 60(7): 1186–8.

Swope D, Barbano R. Treatment recommendations and prac¬tical applications of botulinum toxin treatment of cer¬vical dysto-nia. Neurol Clin 2008; 26(Suppl 1): 54–65.

Brin MF, Comella CL, Jankovic J, Lai F, Naumann M. CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low im¬munogenicity by mouse protection assay. Mov Disord 2008; 23(10): 1353–60.

Gregori B, Agostino R, Bologna M, Dinapoli L, Colosimo C, Accornero N, et al. Fast voluntary neck movements in pa¬tients with cervical dystonia: A kinematic study before and after therapy with botulinum toxin type A. Clin Neuro¬physiol 2008; 119(2): 273–80.

Objavljeno
2020/12/21
Broj časopisa
Vol. 75 Br. 10 (2018): Vojnosanit Pregl 2018; October Vol. 75 (No. 10)
Rubrika
Kratko saopštenje